AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study

Completed

Conditions studied: Age Related Macular Degeneration

In brief

The purpose of this study is to identify whether changes in age-related macular degeneration (AMD) over time as seen with spectral domain optical coherence tomography (SDOCT) imaging, can be used to predict vision loss and the advancement of AMD in people at moderate to high risk for progression.

Key facts

Study ID

NCT00734487

Run by

Duke University

People needed

470

Starts

2008-06-01

Expected to finish

2015-08-01

Last updated by the study team

2025-10-14

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• AMD subjects and controls
• Men and women between the ages of 50 and 85 years
• AMD subjects
• Enrollment in the AREDS 2 trial;
• Macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye

You may not qualify if…

• Ocular media not clear enough to allow good fundus photography.

Where it is running

• Emory University Eye Center — Atlanta, Georgia, United States
• National Eye Institute — Bethesda, Maryland, United States
• Duke University Eye Center — Durham, North Carolina, United States
• Devers Eye Center — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.